Huiyu's operations emphasize its capacity to serve medicines to patients worldwide. Its mission to ensure that essential medications are accessible to patients and healthcare systems globally.

A notable aspect of Huiyu's Generic drugs is its contribution to the production of anti-cancer generic injectables and active pharmaceutical ingredients (APIs), as well as its CDMO/CMO services. Huiyu's importance not only in manufacturing its own products but also in enabling other companies to produce their medications.

Huiyu's commitment providing affordability and accessibility drugs is evident in its focus on developing generic medicines. By increasing the availability of generic versions of expensive medications, Huiyu aims to enhance patient access to necessary treatments, potentially leading to significant savings for healthcare providers. This effort is particularly concentrated on generic injectables, with oncology as a major therapeutic focus, reflecting a strategic approach to address critical healthcare needs.

Huiyu also offers affordable medicines that is attributed to its comprehensive control over the value chain, from ingredient production to distribution. This integrated model, combined with innovation and process strengths, provides Huiyu with a competitive cost advantage. Additionally, Huiyu's expertise in regulation and intellectual property is crucial for ensuring that its medicines meet regulatory standards and are accessible to a global audience.

Huiyu's ethical business practices and commitment to quality and integrity highlight its dedication not only to the outcomes of its work but also to the manner in which it conducts business. This dual focus on product and process integrity is essential for building trust with patients, healthcare providers, and partners in the pharmaceutical industry.

The research and development of chemical generic drugs focuses on anti-cancer drugs urgently needed in clinic, and gradually expands to other indications as the development goal; carries out the optimization research on listed drugs, improves the existing technologies or achievements at home and abroad in a systematic and large-scale manner, and forms a leading engineering technology in China.

Huiyu plans to continue large-scale research and development of injection varieties with high clinical value, large market scale, high technical threshold, products that have earlier passed the quality and efficacy equivalence evaluation and less competitive, and carry out research and development, production and listing of relevant products according to the high standard requirements of quality and efficacy equivalence evaluation to improve Huiyu’s product line.

Huiyu will undertake the research and development of improved complex injection drugs with high clinic value, based on the specific clinical needs, such as to improve the curative effect of the existing drugs in the market, to reduce toxicity, and to optimize administration method and cycle. Through improvement, the efficacy, safety or compliance of drugs can be greatly improved in order to meet the unmet clinical needs.

Huiyu will also carry out the research and development of generic drugs of complex injections. Select drugs with great clinical value, high technical barriers and low competition in the international and domestic markets, and select complex injections with obvious competitive advantages in anti-cancer or related fields for research and realize technological innovation, to overcome the existing technical barriers of API and excipients for equivalence evaluation of complex injections, technical barriers of preparation technology and large-scale production, limitations of production equipment and difficulty in quality control, so as to achieve the production cost and quality of developed complex injections equal to or even better than reference preparations, and improve the market competition of products.